A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors

Exclusion criteria

• . Patients with more than one cancer.
• . Received CDH17-targeting anti-tumor therapy; received other investigational product, systemic corticosteroids or surgery for major organs within 4 weeks prior to the first dose; received anti-tumor therapy within 3 weeks or within 5 half-lives prior to the first dose, whichever is shorter; received radiotherapy within 2 weeks prior to the first dose; received potent CYP3A4 inducers or inhibitors within 2 weeks prior to the first dose or 5 half-lives of investigational product, whichever is longer.
• . ≥Grade 2 toxic reaction or abnormal value of laboratory test caused by previous anti-tumor treatment
• . Symptomatic Central nervous system and/or meninges metastasis.
• . History of severe cardiovascular diseases
• . Cerebrovascular accident, pulmonary embolism, or deep venous thrombosis within 3 months prior to the first dose, implantable venous infusion port or catheter-related thrombosis, or superficial venous thrombosis
• . History of previous or combined interstitial pneumonia, current interstitial pneumonia, or suspected interstitial pneumonia that cannot be ruled out through imaging during screening, severe chronic obstructive pulmonary disease with respiratory failure, severe pulmonary dysfunction, symptomatic bronchospasm, etc.
• . Poorly controlled pleural, peritoneal, and pelvic effusion, or combined pericardial effusion